{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-007129","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2023-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.912717+00:00","generated_at":"2026-06-09T23:56:48.986902+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Sunshine Biopharma warrant holders approve amendment reducing exercise price to $0.11","bullets":["Warrant holders approved amendment to reduce Tradeable Warrants exercise price to $0.11.","736,242 warrants voted in favor (76.4% of 963,693 outstanding), 62,429 against, 3,930 abstentions.","Amendment also eliminates restriction on CEO Steve Slilaty's voting rights under Series B Preferred Stock.","Special meeting of warrant holders held on October 12, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-007129","json":"https://secwatch.observer/filing/0001683168-23-007129.json","markdown":"https://secwatch.observer/filing/0001683168-23-007129.md","text":"https://secwatch.observer/filing/0001683168-23-007129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823007129/0001683168-23-007129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823007129/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:56:48.986902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e30bad61a796c5bdcc53f2202bf7c23ae47fa75","claim":"Sunshine Biopharma Inc. shareholders approved Amend the Warrant Agent Agreement to reduce the exercise price of Tradeable Warrants to $0.11 and eliminate the provision prohibiting the CEO from exercising voting rights under his Series B Preferred Stock at the 2023-10-12 meeting.","evidence_excerpt":"Holders of 736,242 Tradeable Warrants voted in favor of the amendment (representing 76.4% of 963,693 outstanding Tradeable Warrants), votes against were 62,429, and there were 3,930 abstentions.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823007129/0001683168-23-007129-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-12"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}